Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia
Andrew A. Lane(Harvard University), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Donna Neuberg(Otsuka (Japan)), Eric S. Winer(Providence College), Maximilian Stahl(Harvard University), Anthony S. Stein(City of Hope), Marina Konopleva(The University of Texas MD Anderson Cancer Center), Marlise R. Luskin(Harvard University), Rebecca Leonard(Dana-Farber Cancer Institute), Rahul S. Vedula(Harvard University), Jada L. Garzon(Harvard University), Julia Keating(Dana-Farber Cancer Institute), Martha Wadleigh(Dana-Farber Cancer Institute), Ilene Galinsky(Dana-Farber Cancer Institute), Christopher R. Reilly(Dana-Farber Cancer Institute), Richard M. Stone(Dana-Farber Cancer Institute), Siyang Ren(Dana-Farber Cancer Institute), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Tariq I. Mughal(Tufts University), Evangeline G. Raulston(Harvard University), Kristen E. Stevenson(Dana-Farber Cancer Institute), Ira Gupta(Io Therapeutics (United States)), Jacqueline S. Garcia(Dana-Farber Cancer Institute), Emilie Baxter(Harvard University), Christopher Brooks(Io Therapeutics (United States))
Cited by 45
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k